Histone Lysine Demethylase Inhibitors

Area of Science:

• Biochemistry
• Oncology
• Pharmacology

Background:

• Dynamic regulation of histone modifications is crucial for genomic stability and cell identity.
• Dysregulation of histone lysine demethylases is implicated in various blood and solid tumors.
• Demethylases are recognized as significant therapeutic targets in oncology.

Purpose of the Study:

• To review the link between histone demethylases and cancer.
• To provide a comprehensive overview of current demethylase inhibitors.
• To discuss the structure, specificity, and therapeutic utility of these inhibitors.

Main Methods:

• Literature review of demethylase inhibitors and their role in cancer.
• Analysis of recent advances in high-throughput screening and drug design.
• Examination of structure-activity relationships for demethylase inhibitors.

Main Results:

• Histone demethylase inhibitors have demonstrated improved specificity and in vivo efficacy.
• Several demethylase inhibitors are currently undergoing clinical evaluation.
• Ongoing research suggests potential for further development and clinical translation.

Conclusions:

• Demethylase inhibitors represent a promising class of targeted cancer therapies.
• Advances in medicinal chemistry are enhancing the potential of these drugs.
• The progression of demethylase inhibitors into clinical trials highlights their therapeutic relevance.